UNSPSC 51123000: Antiarrythmic alkaloids

This classification denotes organic nitrogenous bases, which chemists usually extract from animal and vegetable sources (and thereafter synthesize the same), substances which called alkaloids, that prevent or treat irregular heartbeat, disturbances of normal rhythmic heart beating, or normal operation of myocardial contraction, thus the term ANTIARRYTHMIC ALKALOIDS.

UNSPSC 51123000 Antiarrhythmic alkaloids is a Class code encompassing emergency and critical-care cardiac medications supplied to fire departments, EMS services, and healthcare systems managed through state and local procurement vehicles. State and local governments buy specific injectable antiarrhythmic formulations—epinephrine, adenosine, diltiazem, and labetalol—in measured unit quantities tied to operational protocols and expiration-management requirements. Soliciting bodies include city fire and rescue departments, state health and human services agencies, and multi-state cooperative purchasing alliances. The Tampa Fire Rescue bid, for example, specified discrete unit counts of four medication line items with nine-month minimum shelf life and ten-day delivery cycles, reflecting operational inventory discipline. Broader programs like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP treated antiarrhythmic alkaloids as part of a generic multi-source pharmaceutical portfolio supplied through authorized wholesalers to distributed state and local healthcare facilities, requiring vendors to hold current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance and maintain contractual relationships with at least two of three designated national wholesalers.

Recent activity centers in Florida and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) with an April 8, 2026 response date and estimated contract value of $40,000.00, with a five-percent Small Local Business Enterprise (SLBE) sheltered-market discount available. The MMCAP RFP, administered by the Minnesota Department of Administration's Office of State Procurement and serving participating state and local governments including Oregon, closed March 26, 2026, and awards were effective July 1, 2026, with two-year contract terms and optional extensions. The Texas Health and Human Services Commission issued a Request for Information (RFI) in early April 2026 to explore direct-to-manufacturer pharmacy programs, though this sought market intelligence rather than immediate medication procurement. Vendors responding to these codes should expect detailed product specifications including National Drug Codes (NDC), strength, dosage form, packaging, and manufacturing location; compliance documentation for accessibility (WCAG 2.2 and Section 508), hazard communication (OSHA Safety Data Sheets), and pharmaceutical manufacturing standards; and insurance coverage minimums ranging from $2 million to $5 million depending on the scope.